Autor(es): Silva, V ; Cerqueira, F ; Nazareth, N ; Medeiros, R ; Sarmento, A ; Sousa, E ; Pinto, M
Data: 2019
Identificador Persistente: https://hdl.handle.net/10216/136256
Origem: Repositório Aberto da Universidade do Porto
Assunto(s): Cytokines; Macrophages; Melanoma; Xanthones
Xanthones have been suggested as prospective candidates for cancer treatment. 1,2-dihydroxyxanthone (1,2-DHX) is known to interfere with the growth of several cancer cell lines. We investigated the effects of 1,2-DHX on the growth of the A375-C5 melanoma cell line and THP-1 human macrophage activity. 1,2-DHX showed a moderate growth inhibition of A375-C5 melanoma cells (concentration that causes a 50% inhibition of cell growth (GI50 ) = 55.0 ± 2.3 µM), but strongly interfered with THP-1 human macrophage activity. Supernatants from lipopolysaccharide (LPS)-stimulated THP-1 macrophage cultures exposed to 1,2-DHX significantly increased growth inhibition of A375-C5 cells, when compared to supernatants from untreated LPS-stimulated macrophages or to direct treatment with 1,2-DHX only. 1,2-DHX decreased THP-1 secretion of interleukin-1ß (IL-1ß) and interleukin-10 (IL-10), but stimulated tumor necrosis factor-a (TNF-a) and transforming growth factor-ß1 (TGF-ß1) production. This xanthone also inhibited nitric oxide (NO) production by RAW 264.7 murine macrophages, possibly through inhibition of inducible NO synthase production. In conclusion, these findings suggest a potential impact of 1,2-DHX in melanoma treatment, not only due to a direct effect on cancer cells but also by modulation of macrophage activity.
